SCHEMBL935487

SCHEMBL935487

O=C(O)CNC(=O)c1c(O)c2ccc(-c3ccc(Cl)cc3)cc2oc1=O

nearest known ligand 0.67

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.48
EGLN1 Q9GZT9 1/20 0.46
EGLN3 Q9H6Z9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL934454 0.91
SCHEMBL2762108 0.91 EGLN2 (0.49) HIF1AEGLN1EGLN3
SCHEMBL934445 0.90 EGLN1 (0.49) HIF1AEGLN1EGLN3
SCHEMBL934092 0.90 HIF1A (0.48) HIF1A
SCHEMBL933678 0.89 EGLN1 (0.53) EGLN1EGLN3
SCHEMBL10009166 0.88 HIF1A (0.46) HIF1A
SCHEMBL934249 0.88 HIF1A (0.48) HIF1A
SCHEMBL11933994 0.88 ALDH1A1 (0.42)
SCHEMBL10009619 0.86 HIF1A (0.53) HIF1A
SCHEMBL10008242 0.86 EGLN1 (0.51) EGLN1EGLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2454249-B1 COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF BEIJING BETTA PHARMACEUTICALS CO LTD (CN) 2018-09-19 EP claimed
US-8742138-B2 Compounds as hypoxia mimetics, and compositions and uses thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2014-06-03 US claimed
US-20120172399-A1 COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) 2012-07-05 US claimed
EP-2454249-B1 COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF BEIJING BETTA PHARMACEUTICALS CO LTD (CN) 2018-09-19 EP disclosed
US-8742138-B2 Compounds as hypoxia mimetics, and compositions and uses thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2014-06-03 US disclosed
US-8742138-B2 Compounds as hypoxia mimetics, and compositions and uses thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2014-06-03 US disclosed
US-8742138-B2 Compounds as hypoxia mimetics, and compositions and uses thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2014-06-03 US disclosed
US-20120172399-A1 COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) 2012-07-05 US disclosed
US-20120172399-A1 COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) 2012-07-05 US disclosed
US-20120172399-A1 COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) 2012-07-05 US disclosed
EP-2454249-A1 COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF Zhejiang Beta Pharma Inc. (CN) 2012-05-23 EP disclosed
CN-102164905-A Compounds, compositions, and uses thereof as hypoxia mimetics BEIJING BETA PHARMA INC 2011-08-24 CN disclosed
WO-2011006355-A1 COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF BEIJING BETA PHARMA INC. (CN) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172399-A1 COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF HIF1AN, HIF1A, EGLN3 HIF1A 2/4885EGLN1 5/4885EGLN3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.